(Q39437884)

12 September 2017

title

Rapid and sustained efficacy of mizolastine 10 mg once daily in seasonal allergic rhinitis (English)

1 reference

12 September 2017

M Stern

1

1 reference

12 September 2017

P Blondin-Ertzbischoff

2

1 reference

12 September 2017

M Murrieta-Aguttes

3

1 reference

12 September 2017

C Hardwicke

4

1 reference

12 September 2017

E B Emmerson

5

1 reference

12 September 2017

M S Judd

6

1 reference

12 September 2017

publication date

1 December 1998

1 reference

Journal of International Medical Research

12 September 2017

published in

1 reference

12 September 2017

volume

26

1 reference

12 September 2017

issue

6

1 reference

12 September 2017

page(s)

292-303

1 reference

Incidence of allergic rhinitis in general practice, 1981-92.

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

The pharmacology and use of H1-receptor-antagonist drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Can an antihistamine delay appearance of hay fever symptoms when given prior to pollen season?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F030006059802600603

10.1177/030006059802600603

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference